Long COVID and the kidney
- PMID: 40908304
- DOI: 10.1038/s41581-025-00997-4
Long COVID and the kidney
Abstract
Long coronavirus disease (COVID) - commonly defined as symptoms and/or long-term effects that persist for at least 3 months after acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and cannot be explained by an alternative diagnosis - is a complex, multifaceted and heterogeneous disease that affects many organ systems, including the kidney. COVID-19 can cause acute kidney injury, and several studies have reported an increased risk of chronic kidney disease (CKD) following COVID-19, suggesting that CKD can be a manifestation of long COVID. Furthermore, patients with CKD are at an increased risk of severe COVID-19 and of long COVID. COVID-19 has also been associated with the development of COVID-19-associated nephropathy, which is a collapsing form of focal segmental glomerulosclerosis, and an increased incidence of new-onset vasculitis. Some early reports described associations of COVID-19 and/or SARS-CoV-2 vaccines with relapse or new-onset of other glomerular diseases, but this link was not confirmed in large population-based studies. SARS-CoV-2 vaccination reduces the risk of COVID-19 and long COVID and is particularly important for protecting vulnerable populations such as patients with CKD. Structured long-term follow-up of patients with COVID-19 and post-infectious sequelae is needed to provide further insight into the trajectory of long COVID and enable identification of those at risk of CKD.
© 2025. Springer Nature Limited.
Conflict of interest statement
Competing interests: U.A. reports no competing interests; V.I. has received a Long-term Fellowship grant from the European Renal Association (ERA) and is an Editorial Board member of NDT; S.B. reports consultancy fees from AstraZeneca, Bayer and GSK; A.K. reports consulting fees from Amgen, AstraZeneca, Boehringer Ingelheim, CSL Vifor, Delta4, GlaxoSmithKline, Novartis, Otsuka, Roche and Walden Biosciences, all outside of the submitted work. A.K. serves as an Associate Editor of Glomerular Diseases and an Editor of NDT. M.J.S. reports personal fees from NovoNordisk, Jansen, Mundipharma, AstraZeneca, Esteve, Fresenius, Ingelheim Lilly, Vifor and ICU, and grants and personal fees from Boehringer Ingelheim; A.B. received consultancy fees from Amgen, AstraZeneca, Boehringer Ingelheim, CSL Vifor, Otsuka and Sobi and payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events from AstraZeneca, Bayer, Boehringer Ingelheim, ChemoCentryx, CSL Vifor, Fresenius, GlaxoSmithKline and Otsuka; A.B. is an Editorial Board member of CKJ.
References
-
- A Long COVID Definition: A Chronic, Systemic Disease State with Profound Consequences. (National Academies Press, 2024). https://doi.org/10.17226/27768 .
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous